Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
As the SELECT trial nears completion, a similar large trial was launched in autumn 2022, but this one involves a new wrinkle on GLP-1 receptor agonism that appears to yield even greater weight loss
Zepbound: Combining GLP-1 and GIP Agonists Zepbound, available as a weekly injection, targets two hormones to enhance weight loss
In individual trials, observation times were highest in the CVOTs (a total of 6,716 patient-years in SUSTAIN 6 and 4,182 patient-years in PIONEER 6)
In the newborn female SE offspring, mitochondrial fission was reduced, however markers of fusion and the autophagosome were increased, which may preserve the function of mitochondria
Please complete the online application using the most up-to-date version available here
